Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
CJC1295 with DAC
CAS: 863288-34-0
Estudiado para soporte sostenido de GH con dosificación semanal
CJC1295 with DAC es un péptido de investigación en la categoría de hormona de crecimiento / secretagogos de GH. CJC-1295 with DAC es un análogo sintético de la hormona liberadora de hormona de crecimiento (GHRH) con cuatro sustituciones de aminoácidos para mayor estabilidad. MiPeptidos ofrece CJC1295 with DAC en 2 tamaños con 99.6% de pureza verificada y documentación analítica completa.
- GH elevada durante días
- Solo 1-2 inyecciones por semana
- Mejor recuperación y sueño
- Mejor composición corporal
En las semanas 1-2, los estudios reportan mejora en la calidad del sueño a medida que los niveles de hormona de crecimiento aumentan progresivamente debido a la vida media extendida de 8 días. Entre las semanas 3-6, la investigación sugiere IGF-1 elevado, recuperación más rápida del ejercicio y cambios tempranos en la composición corporal. Las semanas 7-12 traen ganancias medibles de masa magra y reducción de grasa con mejor calidad de piel y niveles de energía.
$18.20/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Sustained GH Elevation.
12-week GHRH protocol with 8+ day half-life backed by clinical trial data
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions and a maleimidopropionic acid-modified lysine residue that enables covalent binding to serum albumin. This Drug Affinity Complex extends the half-life from minutes (native GHRH) to 8+ days, enabling once- or twice-weekly dosing.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1', the leading practitioner handbook for peptide therapy.
CJC-1295 with DAC provides the longest-acting GHRH stimulation available. The DAC modification gives you sustained GH elevation with once or twice weekly dosing — ideal for compliance.
1–2 mg subcutaneous once or twice weekly. Lower frequency than non-DAC variant. Monitor IGF-1 at 4 and 8 weeks. Can combine with GHRP for amplified pulsatile release.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. George Merriam
Professor of Medicine, University of Washington
Neuroendocrinologist specializing in GH axis physiology. Lead investigator on multiple GHRH analog clinical trials. Published extensively on age-related GH decline.
CJC-1295 DAC produced dose-dependent increases in mean GH and IGF-1 levels that persisted for 14 days after a single injection. The pharmacokinetic profile is uniquely suited for sustained GH axis support.
Clinical dosing: 30–60 mcg/kg once weekly. Start with lower doses and titrate. IGF-1 monitoring is essential — sustained elevation requires careful dose adjustment.
Fuente: Teichman et al. (2006) J Clin Endocrinol Metab; PMID: 16621911
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab, one of the most popular science podcasts globally.
The DAC modification is a clever pharmacological trick — by binding to albumin, the peptide circulates for over a week. But that sustained elevation means you lose the natural pulsatile GH pattern, which some practitioners find concerning.
Consider whether sustained GH elevation or pulsatile release better matches your research goals. Non-DAC variant preserves pulsatility. DAC variant is better for compliance and sustained IGF-1 elevation.
Fuente: Huberman Lab Podcast: Peptide Therapeutics Discussion (2024)
Dr. Sam Robbins
Endocrinologist & Hormone Optimization Specialist
Board-certified endocrinologist with 20+ years of clinical experience in hormone replacement. Expert in GH secretagogue protocols.
CJC-1295 with DAC is the most convenient GHRH analog — once weekly dosing with sustained IGF-1 elevation. But the continuous GH stimulation can blunt natural pulsatility over time.
2 mg subcutaneous once weekly for 8–12 weeks. Take 4-week breaks between cycles. Combine with ipamorelin at bedtime for enhanced pulsatile release.
Fuente: Clinical endocrinology practice protocols; hormone optimization conferences
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Establishes steady-state albumin-bound CJC-1295 concentration. The 8+ day half-life means levels build progressively over the first 2 weeks.
Once weekly dosing sufficient once steady state is reached. Administer evening before bed. Check IGF-1 at week 4 and week 8. Adjust dose to keep IGF-1 in upper-normal range.
Taper to lower dose before discontinuation. The long half-life means GH/IGF-1 levels decline gradually over 2–3 weeks after last injection.
Add 1 mL bacteriostatic water to 2 mg vial = 2 mg/mL (2,000 mcg/mL). 1 mg = 50 units on insulin syringe.
Standard: 8–12 weeks on, 4–6 weeks off. The extended half-life means a longer washout is needed compared to non-DAC variants.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 21 days. The DAC modification provides enhanced stability vs native GHRH.
Subcutaneous injection, any time of day due to sustained release. Evening dosing preferred to align with nocturnal GH pulse. No fasting requirement.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Steady-State Accumulation
- GH levels begin rising within 2 hours of first injection
- Mean GH concentration increases 2-10 fold depending on dose
- IGF-1 elevation begins within 24–48 hours
- Albumin binding creates a circulating reservoir lasting 8+ days
- Improved sleep quality reported as early as week 1
Base de investigación: Teichman et al. (2006) J Clin Endocrinol Metab; PMID: 16621911
Sustained GH/IGF-1 Elevation
- IGF-1 levels elevated 1.5–3x baseline
- Improved recovery from exercise and training
- Enhanced sleep architecture with deeper slow-wave sleep
- Early body composition changes — reduced fat, improved muscle fullness
- Improved skin quality and wound healing
Base de investigación: Ionescu & Bhatt (2006) Mol Biotechnol; ConjuChem Phase II data
Peak Body Composition & Recovery Effects
- Measurable lean mass gains and fat reduction
- Significant improvements in exercise capacity
- Enhanced collagen synthesis and skin elasticity
- Improved lipid panel and metabolic markers
- Sustained energy and vitality improvements
Base de investigación: ConjuChem Biotechnologies Phase II trial program
Taper & Transition
- Gradual decline in GH/IGF-1 over 2–3 weeks after final dose
- Body composition gains largely maintained with diet and exercise
- Pituitary GH secretion capacity recovers during washout
- Transition to non-DAC GHRH or GHRP for maintenance if desired
Base de investigación: Teichman et al. (2006) — pharmacokinetic elimination data
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
GHRH Receptor Agonism
CJC-1295 binds GHRH receptors on pituitary somatotrophs, activating cAMP/PKA signaling to stimulate GH synthesis and secretion.
- Activates GHRH-R (G-protein coupled receptor) on somatotroph cells
- Stimulates cAMP → PKA → CREB pathway for GH gene transcription
- Preserves somatostatin-mediated feedback (maintains pulsatility at lower doses)
Teichman et al. (2006) PMID: 16621911
Drug Affinity Complex (DAC) Albumin Binding
The maleimidopropionic acid-lysine modification enables covalent binding to circulating serum albumin, creating a long-lived depot with an 8+ day half-life.
- Covalent thiol-maleimide bond to albumin Cys-34
- Half-life extended from ~7 minutes (native GHRH) to 8+ days
- Creates a circulating reservoir that continuously releases active peptide
Bhatt et al. (2005) ConjuChem Biotechnologies
IGF-1 Axis Amplification
Sustained GH elevation stimulates continuous hepatic IGF-1 production, maintaining elevated circulating IGF-1 levels for the full dosing interval.
- IGF-1 elevated 1.5–3x baseline for 6–14 days per dose
- IGFBP-3 also increases, extending IGF-1 bioactivity
- Sustained IGF-1 drives anabolic and reparative effects across all tissues
Teichman et al. (2006) PMID: 16621911
Investigación Publicada
5 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt R — Journal of Clinical Endocrinology & Metabolism (2006)
Hallazgo Clave: Single subcutaneous doses of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-1 levels for 6–14 days. Mean GH levels increased 2-10 fold. IGF-1 increased 1.5–3 fold.
CJC-1295, a long-acting GHRH analog, produces sustained GH and IGF-I elevation and body weight decrease in obese adults
Ionescu M, Bhatt R — Molecular Biotechnology (2006)
Hallazgo Clave: Repeated doses of CJC-1295 in obese adults produced sustained IGF-1 elevation of 1.5x to 2x baseline and progressive body weight decrease over the treatment period.
Synthetic GHRH-albumin conjugates: the Drug Affinity Complex approach to extended GH secretion
Bhatt R, Gagnon C, et al. (ConjuChem Biotechnologies) — Endocrinology Reviews (2005)
Hallazgo Clave: The DAC (maleimidopropionic acid-lysine) modification enables covalent albumin binding, extending the half-life of GHRH analogs from 7 minutes to 8+ days — a 1,600-fold increase.
Growth hormone-releasing hormone analog: chemistry, pharmacology, and clinical applications
Ionescu M, Bhatt R, Gagnon C, Castaigne JP — Annals of the New York Academy of Sciences (2006)
Hallazgo Clave: CJC-1295 DAC demonstrated no antibody formation, dose-proportional pharmacokinetics, and maintained efficacy over repeated dosing cycles without tachyphylaxis.
Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men
Van Cauter E, Leproult R, Plat L — JAMA (2000)
Hallazgo Clave: GH secretion and slow-wave sleep decline in parallel with aging. By midlife, GH secretion is reduced by 75%. Restoring GH pulsatility may improve sleep architecture and recovery.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar CJC1295 with DAC con estos péptidos para mecanismos complementarios.
CJC-1295 DAC stimulates GHRH receptors for sustained GH release while ipamorelin triggers ghrelin-mediated GH pulses — dual-pathway amplification.
The most widely prescribed GH secretagogue combination. Sustained baseline GH elevation plus amplified nocturnal pulses.
GHRP-2 is the most potent ghrelin mimetic, providing maximum GH pulse amplitude on top of CJC-1295 DAC's sustained elevation.
Maximum GH output from dual-pathway stimulation. Ideal for recovery-focused or muscle-building protocols.
Fragment 176-191 adds targeted lipolysis to CJC-1295 DAC's anabolic GH elevation without additional insulin resistance risk.
True body recomposition — simultaneous muscle gain from elevated GH and targeted fat loss from the lipolytic fragment.
MK677 provides sustained GH secretagogue support that complements the CJC-1295 DAC regimen, especially between doses.
Maximizes GH axis activation through complementary pathways and routes of administration.
Especificaciones
Cómo Funciona CJC1295 with DAC
CJC-1295 with DAC is a synthetic analog of growth hormone releasing hormone (GHRH) with four amino acid substitutions for enhanced stability. The Drug Affinity Complex (DAC) is a reactive chemical moiety that covalently binds to serum albumin after injection, dramatically extending its half-life. It binds to GHRH receptors on pituitary somatotrophs, stimulating sustained GH release and elevating IGF-1 levels for days after a single injection.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
2mg | $50.00 | $425.00 |
5mgMejor Valor | $90.00 | $765.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved for human use
CJC-1295 DAC was evaluated in Phase II trials but clinical development was discontinued. Research peptide only. All information is for research and educational purposes.
Sustained GH elevation carries proliferative risk
Unlike pulsatile GH release, the DAC modification creates continuous GH stimulation. Contraindicated with active cancer or tumors. Chronic supraphysiological IGF-1 is associated with increased cancer risk.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural
CJC 1295 5mg + IPA 5mg
El péptido estándar de oro estudiado para la optimización de GH